tiprankstipranks
GlaxoSmithKline (GB:GSK)
LSE:GSK
Want to see GB:GSK full AI Analyst Report?

GlaxoSmithKline (GSK) Price & Analysis

1,154 Followers

GSK Stock Chart & Stats

1919.50 p
17.50 p(0.91%)
At close: 4:00 PM EDT
1919.50 p
17.50 p(0.91%)

Bulls Say, Bears Say

Bulls Say
High Profitability And Cash GenerationSustained high gross and operating margins with strong trailing‑12M operating and free cash flow create a durable funding base for R&D, dividends and strategic reinvestment. Reliable cash generation supports long‑term product development and shareholder returns even through cyclical softness.
Late‑stage Pipeline And R&D ReallocationConcentrating capital and talent on 7 late‑stage assets and initiating 20+ phase III trials increases probability of new product inflows over the medium term. The Accelerate Growth plan reallocates savings into R&D, boosting structural product replacement potential and future revenue resilience.
Strengthened Equity Base With High ROEA materially stronger equity base and robust return on equity indicate improved balance‑sheet resilience and capital efficiency. This bolsters the company's ability to fund acquisitions, absorb shocks, and invest in growth initiatives without solely relying on external borrowing.
Bears Say
Elevated LeverageMeaningful leverage increases exposure to interest‑rate and refinancing risk and limits strategic flexibility. In a sector with cyclical approvals and lumpy launches, elevated debt raises the cost of managing setbacks and can constrain M&A or R&D pacing if profitability weakens.
Uneven Earnings And Cash ConversionInconsistent conversion of earnings to free cash flow reduces predictability of funds available for R&D, dividends and buybacks. Persistent volatility forces tougher capital allocation choices and increases execution risk for multi‑year programs that depend on steady internal funding.
Loss‑of‑exclusivity Risk (dolutegravir)Dolutegravir patent expiry presents structural top‑line and margin pressure in core HIV revenues absent successful product replacements. The planned savings and reinvestment help, but execution risk remains: late‑stage launches must materialize to replace lost exclusivity and pricing power.

GlaxoSmithKline News

GSK FAQ

What was GlaxoSmithKline’s price range in the past 12 months?
GlaxoSmithKline lowest share price was 1288.60 p and its highest was 2282.00 p in the past 12 months.
    What is GlaxoSmithKline’s market cap?
    GlaxoSmithKline’s market cap is £77.40B.
      When is GlaxoSmithKline’s upcoming earnings report date?
      GlaxoSmithKline’s upcoming earnings report date is Oct 28, 2026 which is in 85 days.
        How were GlaxoSmithKline’s earnings last quarter?
        GlaxoSmithKline released its earnings results on Jul 28, 2026. The company reported 0.505 p earnings per share for the quarter, beating the consensus estimate of 0.465 p by 0.04 p.
          Is GlaxoSmithKline overvalued?
          According to Wall Street analysts GlaxoSmithKline’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does GlaxoSmithKline pay dividends?
            GlaxoSmithKline pays a Quarterly dividend of 17 p which represents an annual dividend yield of 3.47%. See more information on GlaxoSmithKline dividends here
              What is GlaxoSmithKline’s EPS estimate?
              GlaxoSmithKline’s EPS estimate is 0.52.
                How many shares outstanding does GlaxoSmithKline have?
                GlaxoSmithKline has 4,045,395,300 shares outstanding.
                  What happened to GlaxoSmithKline’s price movement after its last earnings report?
                  GlaxoSmithKline reported an EPS of 0.505 p in its last earnings report, beating expectations of 0.465 p. Following the earnings report the stock price went up 3.468%.
                    Which hedge fund is a major shareholder of GlaxoSmithKline?
                    Currently, no hedge funds are holding shares in GB:GSK
                    What is the TipRanks Smart Score and how is it calculated?
                    Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                      Company Description

                      GlaxoSmithKline

                      GSK plc is a global pharmaceutical and healthcare company, deeply involved in the research, development, production, and commercialization of a diverse range of medicinal and wellness products. Its operations span the United Kingdom, the United States, and numerous other international markets. The company structures its operations across four primary divisions: Pharmaceuticals, Pharmaceutical R&D, Vaccines, and Consumer Healthcare. Within its Pharmaceuticals segment, GSK provides treatments addressing a wide array of therapeutic areas. These include respiratory conditions, HIV, immuno-inflammatory diseases, oncology, viral infections, central nervous system disorders, cardiovascular and urogenital health, metabolic imbalances, bacterial infections, and dermatological issues. The Consumer Healthcare division offers products across categories such as wellness, oral hygiene, nutritional supplements, and skin health. These consumer offerings come in a variety of formats, including oral dosage forms (e.g., tablets, syrups, lozenges, gummies, soft chews, effervescents), topical applications (e.g., gels, creams, patches, lip balms), nasal sprays, and a comprehensive range of oral hygiene products (e.g., toothpastes, mouthwashes, denture care items), alongside other specialized formulations like infant drops and wipes. GSK actively engages in various collaborative ventures. Its collaboration agreements include partnerships with 23andMe, Lyell Immunopharma, Inc., Novartis, Sanofi SA, Surface Oncology, Progentec Diagnostics, Inc., Alector, Inc., and CureVac AG. Additionally, the company maintains strategic alliances with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. Originally established in 1715, the company operated under the name GlaxoSmithKline plc until its rebranding to GSK plc in May 2022. Its corporate headquarters are situated in Brentford, United Kingdom.

                      GlaxoSmithKline (GSK) Earnings & Revenues

                      GSK Stock 12 Month Forecast

                      Average Price Target

                      2,135.85 p
                      ▲(11.27% Upside)
                      {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1344":"1,344 p","3011":"3,011 p","1760.75":"1,760.8 p","2177.5":"2,177.5 p","2594.25":"2,594.3 p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3010,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">3.01K </span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2135.846153846154,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">2.14K </span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1700,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">1.70K </span>\n  </div></div>","useHTML":true}}],"tickPositions":[1344,1760.75,2177.5,2594.25,3011],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1931.5,2014.4615384615386,2097.423076923077,2180.3846153846152,2263.346153846154,2346.3076923076924,2429.269230769231,2512.2307692307695,2595.1923076923076,2678.153846153846,2761.1153846153848,2844.076923076923,2927.038461538462,{"y":3010,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1931.5,1947.2189349112425,1962.9378698224853,1978.6568047337278,1994.3757396449705,2010.094674556213,2025.8136094674555,2041.5325443786983,2057.251479289941,2072.9704142011833,2088.689349112426,2104.408284023669,2120.127218934911,{"y":2135.846153846154,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1931.5,1913.6923076923076,1895.8846153846155,1878.076923076923,1860.2692307692307,1842.4615384615386,1824.6538461538462,1806.8461538461538,1789.0384615384614,1771.2307692307693,1753.423076923077,1735.6153846153848,1717.8076923076924,{"y":1700,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1345.708,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1410.581,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1628.868,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1735.088,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1769.618,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1793.704,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1892.508,"date":1769904000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2160.349,"date":1772323200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 20</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2088.008,"date":1775001600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 21</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1883.864,"date":1777593600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 18</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1842.5,"date":1780272000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1930,"date":1782864000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1931.5,"date":1785542400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      AstraZeneca
                      Hikma Pharmaceuticals
                      Smith & Nephew
                      Beximco Pharmaceuticals Limited Sponsored GDR RegS
                      Haleon PLC
                      Popular Stocks